the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Official Title
Principal Investigator Szmulewitz, Russell
Brief Summary The primary objective of this study is to compare the progression free survival (PFS) of patients with metastatic castration-resistant prostate cancer treated with enzalutamide in combination with LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).
Gender Male
Ages 18 Years
Enrollment 60
Accepts Healthy Volunteers No
Lead Sponsor Sidney Kimmel Comprehensive Cancer CenterOther
Collaborator
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Channing Paller, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Prostate Cancer
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI